A detailed history of Campbell & CO Investment Adviser LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Campbell & CO Investment Adviser LLC holds 17,985 shares of EXEL stock, worth $646,201. This represents 0.04% of its overall portfolio holdings.

Number of Shares
17,985
Holding current value
$646,201
% of portfolio
0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $394,950 - $496,386
17,985 New
17,985 $466,000
Q1 2024

May 10, 2024

BUY
$20.17 - $23.93 $385,408 - $457,254
19,108 New
19,108 $453,000
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $372,431 - $528,957
23,752 New
23,752 $372,000
Q1 2019

May 10, 2019

SELL
$19.6 - $24.76 $362,227 - $457,589
-18,481 Closed
0 $0
Q4 2018

Feb 08, 2019

BUY
$13.65 - $21.8 $252,265 - $402,885
18,481 New
18,481 $403,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.6B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Campbell & CO Investment Adviser LLC Portfolio

Follow Campbell & CO Investment Adviser LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

News

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.